Business Description
EQL Pharma AB
ISIN : SE0005497732
Compare
Compare
Traded in other countries / regions
EQL.Sweden7JK.Germany IPO Date
2013-12-17Description
EQL Pharma AB is a pharmaceutical company engaged in developing and selling medicines to pharmacies and hospitals. The products offered by the company include generics and parallel imports. It operates and markets products to Nordic countries of Sweden, Denmark, Finland and Norway.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.1 | |||||
| Equity-to-Asset | 0.51 | |||||
| Debt-to-Equity | 0.61 | |||||
| Debt-to-EBITDA | 3.32 | |||||
| Interest Coverage | 7.24 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 5.77 | |||||
| Beneish M-Score | -2.73 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 52.6 | |||||
| 3-Year EBITDA Growth Rate | 95.7 | |||||
| 3-Year EPS without NRI Growth Rate | 123.6 | |||||
| 3-Year Book Growth Rate | 24.1 | |||||
| Future 3-5Y Total Revenue Growth Rate | 13.06 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 28.3 | |||||
| 9-Day RSI | 46.97 | |||||
| 14-Day RSI | 54.78 | |||||
| 6-1 Month Momentum % | 45.49 | |||||
| 12-1 Month Momentum % | 6.03 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.28 | |||||
| Quick Ratio | 0.56 | |||||
| Cash Ratio | 0.08 | |||||
| Days Inventory | 209.11 | |||||
| Days Sales Outstanding | 82.65 | |||||
| Days Payable | 84.87 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | 1.01 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 45.34 | |||||
| Operating Margin % | 12.2 | |||||
| Net Margin % | 8.99 | |||||
| FCF Margin % | -19.05 | |||||
| ROE % | 13.72 | |||||
| ROA % | 7.55 | |||||
| ROIC % | 10.13 | |||||
| ROC (Joel Greenblatt) % | 32.42 | |||||
| ROCE % | 17.78 | |||||
| Years of Profitability over Past 10-Year | 6 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 43.06 | |||||
| PE Ratio without NRI | 43.06 | |||||
| Shiller PE Ratio | 127.83 | |||||
| PEG Ratio | 0.38 | |||||
| PS Ratio | 5.05 | |||||
| PB Ratio | 7.1 | |||||
| Price-to-Tangible-Book | 175.83 | |||||
| Price-to-Operating-Cash-Flow | 65.42 | |||||
| EV-to-EBIT | 41.3 | |||||
| EV-to-Forward-EBIT | 17.39 | |||||
| EV-to-EBITDA | 41.3 | |||||
| EV-to-Forward-EBITDA | 15.19 | |||||
| EV-to-Revenue | 5.37 | |||||
| EV-to-Forward-Revenue | 3.43 | |||||
| EV-to-FCF | -29.29 | |||||
| Price-to-Projected-FCF | 11.63 | |||||
| Price-to-Median-PS-Value | 0.94 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.72 | |||||
| Price-to-Graham-Number | 18.43 | |||||
| Price-to-Net-Current-Asset-Value | 301.43 | |||||
| Earnings Yield (Greenblatt) % | 2.42 | |||||
| FCF Yield % | -3.82 | |||||
| Forward Rate of Return (Yacktman) % | 19.81 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
EQL Pharma AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 246.367 | ||
| EPS (TTM) (kr) | 0.98 | ||
| Beta | 0.78 | ||
| Volatility % | 44.42 | ||
| 14-Day RSI | 54.78 | ||
| 14-Day ATR (kr) | 1.532456 | ||
| 20-Day SMA (kr) | 42.045 | ||
| 12-1 Month Momentum % | 6.03 | ||
| 52-Week Range (kr) | 24.7 - 46 | ||
| Shares Outstanding (Mil) | 29.06 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
EQL Pharma AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
EQL Pharma AB Stock Events
| Event | Date | Price(kr) | ||
|---|---|---|---|---|
| No Event Data | ||||
EQL Pharma AB Frequently Asked Questions
What is EQL Pharma AB(XSAT:EQL)'s stock price today?
The current price of XSAT:EQL is kr42.20. The 52 week high of XSAT:EQL is kr46.00 and 52 week low is kr24.70.
When is next earnings date of EQL Pharma AB(XSAT:EQL)?
The next earnings date of EQL Pharma AB(XSAT:EQL) is 2024-05-14.
Does EQL Pharma AB(XSAT:EQL) pay dividends? If so, how much?
EQL Pharma AB(XSAT:EQL) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers